Notable earnings after Tuesday's close
Seeking Alpha · 15h ago
Myriad Genetics Q4 2023 Earnings Preview
Seeking Alpha · 16h ago
Myriad Genetics Earnings Preview
Myriad Genetics is set to give its latest quarterly earnings report on Tuesday. Analysts estimate the company will report an earnings per share of $0.01. Shares of Myriad Genetics were trading at $22.72 as of February 23. The company beat last quarter's earnings by $ 0.05 and shares are up 20.35%.
Benzinga · 22h ago
Weekly Report: what happened at MYGN last week (0219-0223)?
Weekly Report · 1d ago
Weekly Report: what happened at MYGN last week (0212-0216)?
Weekly Report · 02/19 09:12
Weekly Report: what happened at MYGN last week (0205-0209)?
Weekly Report · 02/12 09:11
Piper Sandler Reaffirms Their Hold Rating on Myriad Genetics (MYGN)
TipRanks · 02/08 12:39
Weekly Report: what happened at MYGN last week (0129-0202)?
Weekly Report · 02/05 09:12
An Intrinsic Calculation For Myriad Genetics, Inc. (NASDAQ:MYGN) Suggests It's 37% Undervalued
Using the 2 Stage Free Cash Flow to Equity, Myriad Genetics fair value estimate is US$34.37 Current share price of US$21.61 suggests myriad Genetics is potentially 37% undervalued. We will use a discounted cash flow model to estimate the intrinsic value of the company. Our fair value is 53% higher than the company's analyst price target of US $22.50.
Simply Wall St · 02/02 10:48
Myriad Genetics' Strategic Growth Fuels Bullish Outlook
Seeking Alpha · 01/31 19:23
Goldman Sachs Maintains Buy on Myriad Genetics, Raises Price Target to $31
Benzinga · 01/30 13:59
Peeling Back The Layers: Exploring Myriad Genetics Through Analyst Insights
Myriad Genetics (NASDAQ:MYGN) is a molecular diagnostics company that provides tests to assess risk of developing a disease. Myriad Genetics has an average 12-month price target of $22.2. 5 analysts have shared their insights on the company over the past three months. The company has a strong financial performance and a positive revenue growth rate.
Benzinga · 01/29 16:01
Webull provides a variety of real-time MYGN stock news. You can receive the latest news about Myriad Genetics through multiple platforms. This information may help you make smarter investment decisions.
About MYGN
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, EndoPredict, Foresight, Prequel, Precis Tumor Test, Precise Liquid Test, SneakPeek and GeneSight.